AR124264A1 - COMPOSITIONS AND METHODS FOR PREVENTING BRAIN METASTASIS - Google Patents

COMPOSITIONS AND METHODS FOR PREVENTING BRAIN METASTASIS

Info

Publication number
AR124264A1
AR124264A1 ARP210103404A ARP210103404A AR124264A1 AR 124264 A1 AR124264 A1 AR 124264A1 AR P210103404 A ARP210103404 A AR P210103404A AR P210103404 A ARP210103404 A AR P210103404A AR 124264 A1 AR124264 A1 AR 124264A1
Authority
AR
Argentina
Prior art keywords
metastases
methods
compositions
subject
prevention
Prior art date
Application number
ARP210103404A
Other languages
Spanish (es)
Inventor
Sang Min Lee
Aimee Karis Lin
Boris Kin Lin
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of AR124264A1 publication Critical patent/AR124264A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción proporciona composiciones y métodos que comprenden un compuesto de fórmula (1) administrado para el tratamiento de metástasis en el CNS (por ejemplo, metástasis cerebrales) y para la prevención de metástasis en el CNS (por ejemplo, metástasis cerebrales). La descripción proporciona, dentro de tales composiciones y métodos, el tratamiento y/o la prevención de metástasis en el CNS (por ejemplo, metástasis cerebrales) en un sujeto que padece un cáncer, incluido un cáncer asociado a RET. Reivindicación 1: Un método para prevenir metástasis cerebrales en un sujeto que tiene un cáncer, que comprende administrar, al sujeto que necesita prevención, selpercatinib o una sal farmacéuticamente aceptable de este, o una composición que comprende selpercatinib o una sal farmacéuticamente aceptable de este, en una cantidad eficaz para prevenir metástasis cerebrales en el sujeto.The disclosure provides compositions and methods comprising a compound of formula (1) administered for the treatment of CNS metastases (eg brain metastases) and for the prevention of CNS metastases (eg brain metastases). The disclosure provides, within such compositions and methods, for the treatment and/or prevention of CNS metastases (eg, brain metastases) in a subject suffering from a cancer, including a RET-associated cancer. Claim 1: A method of preventing brain metastases in a subject having cancer, which comprises administering, to the subject in need of prevention, selpercatinib or a pharmaceutically acceptable salt thereof, or a composition comprising selpercatinib or a pharmaceutically acceptable salt thereof, in an amount effective to prevent brain metastases in the subject.

ARP210103404A 2020-12-14 2021-12-07 COMPOSITIONS AND METHODS FOR PREVENTING BRAIN METASTASIS AR124264A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063125085P 2020-12-14 2020-12-14

Publications (1)

Publication Number Publication Date
AR124264A1 true AR124264A1 (en) 2023-03-01

Family

ID=79287609

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103404A AR124264A1 (en) 2020-12-14 2021-12-07 COMPOSITIONS AND METHODS FOR PREVENTING BRAIN METASTASIS

Country Status (3)

Country Link
AR (1) AR124264A1 (en)
TW (1) TW202237118A (en)
WO (1) WO2022132593A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

Also Published As

Publication number Publication date
TW202237118A (en) 2022-10-01
WO2022132593A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
UY28674A1 (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
CO2019015090A2 (en) Treatment methods for cystic fibrosis
CL2020000860A1 (en) Chroman monobactam compounds for the treatment of bacterial infections.
MA40768B1 (en) Mono or di-substituted indole derivatives as dengue virus replication inhibitors
MX2021010106A (en) Inhibitors of integrated stress response pathway.
MX2023001298A (en) Combinations for the treatment of cancer.
BR112013021566A2 (en) compound of formula, or a pharmaceutically acceptable salt or adduct thereof and method of preventing and / or treating an individual comprising administering to said individual a therapeutically effective amount of a compound of formula
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2020013297A (en) Compound for treatment or prevention of liver diseases.
MX2023013683A (en) Fused isoxazolyl compounds as kat6a inhibitors.
RU94044356A (en) Use of 2-phenyl-3-aroylbenzothiophenes for thrombodulin expression increase to inhibit thrombotic disorder, for protein c activation
CL2022002641A1 (en) Agent for treatment of contrast-induced acute kidney injury
AR124264A1 (en) COMPOSITIONS AND METHODS FOR PREVENTING BRAIN METASTASIS
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2019006940A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder.
PH12021550258A1 (en) Cdk8/19 inhibitors
BR112018073556A2 (en) medicament and pharmaceutical composition for the prevention or treatment of trigeminal neuralgia, method for preventing or treating trigeminal neuralgia in an individual, and use of a carbamate compound.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
AU7122501A (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
AR128257A1 (en) COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO STING ACTIVITY
AR057403A1 (en) 4- ANILINO-3-QUINOLINCARBONITRILOS FOR THE TREATMENT OF CANCER
PH12020551620A1 (en) Compositions for preventing or treating dry eye
AR126552A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SYSTEMIC SCLEROSIS
BR112023016459A2 (en) THERAPEUTIC METHODS
AR128051A1 (en) PARP1 INHIBITORS